Recombinant Vesicular Stomatitis Virus-expressing Human Interferon Beta and Sodium-Iodide Symporter

BIOLOGICAL4 trials

Sponsors

Mayo Clinic

Conditions

Advanced Clear Cell Renal Cell CarcinomaAnaplastic Large Cell LymphomaB-Cell Non-Hodgkin LymphomaHistiocytic and Dendritic Cell NeoplasmMetastatic Clear Cell Renal Cell CarcinomaMetastatic Endometrial CarcinomaMycosis FungoidesMyelodysplastic Syndrome

Phase 1

A Vaccine (VSV-hIFNβ-NIS) With or Without Cyclophosphamide and Combinations of Ipilimumab, Nivolumab, and Cemiplimab in Treating Relapsed or Refractory Multiple Myeloma, Acute Myeloid Leukemia or Lymphoma

RecruitingNCT03017820

Mayo ClinicB-Cell Non-Hodgkin Lymphoma, Histiocytic and Dendritic Cell Neoplasm, Myelodysplastic Syndrome +16

Start: 2017-04-04End: 2032-04-01Target: 127Updated: 2026-03-27

VSV-hIFNbeta-NIS With or Without Ruxolitinib Phosphate in Treating Stage IV or Recurrent Endometrial Cancer

Active, not recruitingNCT03120624

Mayo ClinicMetastatic Endometrial Carcinoma, Recurrent Endometrial Adenocarcinoma, Recurrent Endometrial Carcinoma +7

Start: 2017-09-15End: 2028-01-01Updated: 2026-02-04

Intravenous Vesicular Stomatitis Virus in Patients With Peripheral T-cell Lymphoma

RecruitingNCT06508463

Mayo ClinicAnaplastic Large Cell Lymphoma, Mycosis Fungoides, Peripheral T Cell Lymphoma +4

Start: 2024-01-05End: 2032-04-01Target: 21Updated: 2026-03-16

Phase 2

VSV-IFNβ-NIS With Ipilimumab and Nivolumab for the Treatment of Advanced or Metastatic Clear Cell Renal Cell Carcinoma

Not yet recruitingNCT07510334

Mayo ClinicAdvanced Clear Cell Renal Cell Carcinoma, Metastatic Clear Cell Renal Cell Carcinoma, Stage III Renal Cell Cancer AJCC v8 +1

Start: 2026-05-01End: 2033-08-01Target: 18Updated: 2026-04-03

Related Papers

Phase I Trial of Systemic Administration of Vesicular Stomatitis Virus Genetically Engineered to Express NIS and Human Interferon, in Patients with Relapsed or Refractory Multiple Myeloma, Lymphomas, or Histiocytic/Dendritic Cell Neoplasms

Blood2023-11-02

Systemic VSV-IFNβ-NIS oncolytic virotherapy in patients with relapsed refractory T-cell lymphoma.

Journal of Clinical Oncology2023-06-012 citations

Preliminary pharmacokinetic and safety data after a single intravenous infusion of Voyager-V1 (VV1, VSV-IFNβ-NIS) oncolytic virus in patients with relapsed refractory hematologic malignancies.

Journal of Clinical Oncology2023-06-011 citations

Clinical Activity of Single Dose Systemic Oncolytic VSV Virotherapy in Patients with Relapsed Refractory T-Cell Lymphoma

Blood Advances2022-02-1742 citations

An Analysis of Virus Amplification and Antitumor Responses in T-Cell Lymphoma Patients Treated with Voyager-V1 ( VSV-IFNβ-NIS)

Blood2021-11-05

Clinical activity of systemic VSV-IFNβ-NIS oncolytic virotherapy in patients with relapsed refractory T-cell lymphoma.

Journal of Clinical Oncology2021-05-206 citations

Phase I Trial of Systemic Administration of Vesicular Stomatitis Virus Genetically Engineered to Express NIS and Human Interferon Beta, in Patients with Relapsed or Refractory Multiple Myeloma (MM), Acute Myeloid Leukemia (AML), and T-Cell Neoplasms (TCL)

Blood2020-11-044 citations

Abstract CT072: First in human (FIH) dose escalation studies of intravenous administration of VSV-IFNβ-NIS (Voyager-V1™) in Stage IV or recurrent endometrial cancer

Cancer Research2018-07-014 citations